X-376 NEW
| Price | $89 | $122 | $271 |
| Package | 5mg | 10mg | 25mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-07-16 |
Product Details
| Product Name: X-376 | CAS No.: 1365267-27-1 |
| Purity: 98.72% | Supply Ability: 10g |
| Release date: 2025/07/16 |
Product Introduction
Bioactivity
| Name | X-376 |
| Description | X-376 (Ensartinib) is an orally available small molecule inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with potential antineoplastic activity. Upon oral administration, X-396 binds to and inhibits ALK kinase, ALK fusion proteins, and ALK point mutation variants. Inhibition of ALK leads to the disruption of ALK-mediated signaling and eventually inhibits tumor cell growth in ALK-expressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. |
| In vitro | Ensartinib is a selective ALK inhibitor, and provids promising advantages in terms of both Clinicalal activity and safety[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 37 mg/mL (67.59 mM), Sonication is recommended. |
| Keywords | X396 | X-376 | X376 | X 396 | X 376 | MET | Inhibitor | inhibit | HGFR | c-Met/HGFR | cMet/HGFR | c-Met | cMet | Cluster of differentiation 246 | CD246 | Anaplastic lymphoma kinase (ALK) | Anaplastic lymphoma kinase | ALK tyrosine kinase receptor | ALK |
| Inhibitors Related | Entrectinib | Alectinib hydrochloride | DMH-1 | ALK-IN-1 | Capmatinib 2HCl | (±)-Norcantharidin | L-Ascorbic acid 2-phosphate trisodium | Crizotinib | Ceritinib | LDN-193189 2HCl | Cabozantinib S-malate | A 83-01 |
| Related Compound Libraries | Anti-Lung Cancer Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Bioactive Compounds Library Max | Anti-Liver Cancer Compound Library | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $68.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2025-05-12 | |
| $79.00/1kg |
VIP1Y
|
Hebei Zhuanglai Chemical Trading Co Ltd
|
2024-12-17 | |
| $0.00/5mg |
VIP1Y
|
Guangzhou Tosun Pharmaceutical Ltd
|
2025-01-21 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY